NASDAQ:XBIT - XBiotech Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$8.54 -0.05 (-0.58 %)
(As of 02/21/2019 01:14 AM ET)
Previous Close$8.59
Today's Range$8.41 - $8.70
52-Week Range$2.13 - $10.70
Volume50,700 shs
Average Volume158,985 shs
Market Capitalization$305.90 million
P/E RatioN/A
Dividend YieldN/A
Beta0.21
XBiotech Inc., a pre-market biopharmaceutical company, engages in discovering and developing True Human monoclonal antibodies for treating various diseases. The company's lead product is Xilonix, which is also known as MABp1, a therapeutic antibody that neutralizes interleukin-1 alpha, which has completed Phase III clinical trial in Europe for the treatment of symptomatic and advanced colorectal cancer. It has also investigating its lead product candidate in various clinical trials for other inflammatory conditions, including vascular disease, type II diabetes, acne, psoriasis, pyoderma gangrenosum, and hidradenitis suppurativa, as well as staphylococcus aureus infection, influenza, and clostridium difficile infection diseases. XBiotech, Inc. was founded in 2005 and is headquartered in Austin, Texas.

Receive XBIT News and Ratings via Email

Sign-up to receive the latest news and ratings for XBIT and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:XBIT
CUSIPN/A
Phone512-386-2900

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$1.70 per share

Profitability

Net Income$-33,150,000.00

Miscellaneous

Employees51
Market Cap$305.90 million
OptionableOptionable

XBiotech (NASDAQ:XBIT) Frequently Asked Questions

What is XBiotech's stock symbol?

XBiotech trades on the NASDAQ under the ticker symbol "XBIT."

When is XBiotech's next earnings date?

XBiotech is scheduled to release their next quarterly earnings announcement on Friday, March 15th 2019. View Earnings Estimates for XBiotech.

Has XBiotech been receiving favorable news coverage?

News coverage about XBIT stock has trended neutral on Thursday, InfoTrie reports. The research firm identifies negative and positive media coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. XBiotech earned a daily sentiment score of 0.3 on InfoTrie's scale. They also gave news coverage about the biopharmaceutical company a news buzz of 5.0 out of 10, indicating that recent media coverage is somewhat likely to have an impact on the company's share price in the near term.

Who are some of XBiotech's key competitors?

Who are XBiotech's key executives?

XBiotech's management team includes the folowing people:
  • Mr. John Simard, Founder, Pres, CEO & Chairman (Age 57)
  • Dr. Sushma Shivaswamy, Chief Scientific Officer (Age 41)
  • Ms. Queena Han B.A., CPA, C.G.A., VP of Fin. & HR and Sec. (Age 52)
  • Mr. Benjamín Guzmán, Sr. VP of Corp. Strategy & Fin. (Age 63)
  • Dr. William Levis, Interim Medical Director and Member of Scientific Advisory Board

When did XBiotech IPO?

(XBIT) raised $76 million in an IPO on Wednesday, April 15th 2015. The company issued 4,000,000 shares at a price of $18.00-$20.00 per share. WR Hambrecht + Co served as the underwriter for the IPO.

Who are XBiotech's major shareholders?

XBiotech's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Millennium Management LLC (0.14%) and Virtu Financial LLC (0.04%). Company insiders that own XBiotech stock include Fondation Rennes, Queena Han, W Thorpe Mckenzie and W Thorpe Mckenzie. View Institutional Ownership Trends for XBiotech.

Which institutional investors are selling XBiotech stock?

XBIT stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC. Company insiders that have sold XBiotech company stock in the last year include Queena Han, W Thorpe Mckenzie and W Thorpe Mckenzie. View Insider Buying and Selling for XBiotech.

Which institutional investors are buying XBiotech stock?

XBIT stock was acquired by a variety of institutional investors in the last quarter, including Virtu Financial LLC. Company insiders that have bought XBiotech stock in the last two years include Fondation Rennes and W Thorpe Mckenzie. View Insider Buying and Selling for XBiotech.

How do I buy shares of XBiotech?

Shares of XBIT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is XBiotech's stock price today?

One share of XBIT stock can currently be purchased for approximately $8.54.

How big of a company is XBiotech?

XBiotech has a market capitalization of $305.90 million. XBiotech employs 51 workers across the globe.

What is XBiotech's official website?

The official website for XBiotech is http://www.xbiotech.com.

How can I contact XBiotech?

XBiotech's mailing address is 5217 WINNEBAGO LN, AUSTIN TX, 78744. The biopharmaceutical company can be reached via phone at 512-386-2900 or via email at [email protected]


MarketBeat Community Rating for XBiotech (NASDAQ XBIT)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  163 (Vote Outperform)
Underperform Votes:  136 (Vote Underperform)
Total Votes:  299
MarketBeat's community ratings are surveys of what our community members think about XBiotech and other stocks. Vote "Outperform" if you believe XBIT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe XBIT will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/21/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel